Dr. Leslie Bradford, MD
Claim this profileMaine Medical Center- Scarborough Campus
Area of expertise
Ovarian Cancer
Leslie Bradford, MD has run 13 trials for Ovarian Cancer. Some of their research focus areas include:
Fallopian Tube Cancer
Leslie Bradford, MD has run 8 trials for Fallopian Tube Cancer. Some of their research focus areas include:
Affiliated Hospitals
Maine Medical Center- Scarborough Campus
Harold Alfond Center For Cancer Care
Clinical Trials Leslie Bradford, MD is currently running
Mirvetuximab + Bevacizumab
for Ovarian Cancer
GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
Recruiting
2 awards
Phase 3
Selumetinib + Olaparib
for Ovarian and Endometrial Cancer
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of olaparib to selumetinib could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to selumetinib alone.
Recruiting
1 award
Phase 2
More about Leslie Bradford, MD
Clinical Trial Related
2 years of experience running clinical trials · Led 22 trials as a Principal Investigator · 9 Active Clinical Trials
Treatments Leslie Bradford, MD has experience with
- Olaparib
- Paclitaxel
- Bevacizumab
- Carboplatin
- Pembrolizumab
- Cediranib Maleate
Breakdown of trials Leslie Bradford, MD has run
Ovarian Cancer
Fallopian Tube Cancer
Cancer
Endometrial Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Leslie Bradford, MD specialize in?
Leslie Bradford, MD focuses on Ovarian Cancer and Fallopian Tube Cancer. In particular, much of their work with Ovarian Cancer has involved Stage IV patients, or patients who are BRCA1 positive.
Is Leslie Bradford, MD currently recruiting for clinical trials?
Yes, Leslie Bradford, MD is currently recruiting for 9 clinical trials in Scarborough Maine. If you're interested in participating, you should apply.
Are there any treatments that Leslie Bradford, MD has studied deeply?
Yes, Leslie Bradford, MD has studied treatments such as Olaparib, Paclitaxel, Bevacizumab.
What is the best way to schedule an appointment with Leslie Bradford, MD?
Apply for one of the trials that Leslie Bradford, MD is conducting.
What is the office address of Leslie Bradford, MD?
The office of Leslie Bradford, MD is located at: Maine Medical Center- Scarborough Campus, Scarborough, Maine 04074 United States. This is the address for their practice at the Maine Medical Center- Scarborough Campus.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.